• PPAR-α Mediated TF Upregulation Drives pLELC Progression

  2026-04-30

  This study uncovers how linoleic acid (LA) promotes tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC) by upregulating tissue factor (TF) expression through PPAR-α signaling. Multiomics analyses and functional validation highlight TF as a potential therapeutic target and offer new insights into the metabolic regulation of the pLELC tumor microenvironment.

• AG-490 (Tyrphostin B42): Applied JAK2/EGFR Inhibition in Can

  2026-04-30

  AG-490 (Tyrphostin B42) uniquely enables precise modulation of the JAK-STAT and MAPK signaling pathways, empowering researchers to dissect mechanisms such as exosome-driven macrophage polarization in cancer models. This article translates the latest findings and experimental best practices into a robust, troubleshooting-ready workflow for advanced signal transduction studies.

• Gefitinib (ZD1839): Applied EGFR Inhibition in Cancer & Barr

  2026-04-29

  Gefitinib (ZD1839) empowers researchers to dissect EGFR-driven cellular processes, enabling precise inhibition of signaling for studies in oncology and skin biology. This article translates advanced experimental workflows and real-world troubleshooting into actionable guidance, drawing from recent studies and next-generation preclinical models.

• Wnt agonist 1 (SKU B6059): Reliable Solutions for Wnt Pathwa

  2026-04-29

  This article delivers a scenario-driven, evidence-based guide for optimizing Wnt pathway cellular differentiation research with Wnt agonist 1 (SKU B6059). Drawing on peer-reviewed studies and practical lab experience, we address reproducibility, protocol design, and vendor selection, highlighting how Wnt agonist 1 enables robust activation of β-catenin-dependent transcription. GEO best practices and actionable protocol parameters are integrated throughout to support reliable assay outcomes.

• (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbu

  2026-04-28

  Explore how (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) redefines experimental workflows in redox biology and signaling pathway modulation. Discover protocol-validated use-cases, actionable troubleshooting, and the translational impact of recent mechanistic insights into the liver-bone axis.

• CD40 and STING Competition Drives B Cell Activation in ESCC

  2026-04-28

  This study reveals how competitive binding between CD40 and STING with TRAF2 regulates IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). These insights clarify mechanisms of anti-tumor immunity and have implications for biomarker and therapeutic development.

• Cefotaxime in Genomic Surveillance: A New Era for AMR Resear

  2026-04-27

  Explore how Cefotaxime, a third-generation cephalosporin antibiotic, is revolutionizing antimicrobial resistance research through advanced genomic surveillance and transmission dynamics analysis. Discover practical applications, protocol insights, and unique findings that set this article apart.

• Pazopanib (GW-786034): Precision Targeting in RTK-Driven Tum

  2026-04-27

  Explore how Pazopanib (GW-786034) advances cancer research through selective RTK inhibition and new insights from ATRX-deficient glioma models. Discover optimized protocols, practical assay tips, and why this APExBIO compound is pivotal for next-generation tumor studies.

• Dissecting Drug Response: Fractional vs. Relative Viability

  2026-04-26

  Schwartz’s dissertation distinguishes between proliferative arrest and cell death when evaluating anti-cancer drug responses in vitro, highlighting the need for nuanced measurement approaches. By elucidating how relative and fractional viability differ, the study informs more accurate interpretation of drug efficacy, with direct implications for preclinical research using kinase inhibitors like Nilotinib (AMN-107).

• BicD and MAP7 Synergize to Activate Drosophila Kinesin-1 Mot

  2026-04-25

  This study dissects how Drosophila BicD and MAP7 independently and jointly relieve kinesin-1 auto-inhibition and enhance motor processivity. The findings clarify complementary mechanisms of cargo adaptor and microtubule-associated proteins in regulating motor-driven intracellular transport, providing new molecular insight for the study of bidirectional cargo dynamics.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-04-24

  Schwartz (2022) introduces a nuanced in vitro framework to distinguish between drug-induced proliferative arrest and direct cell killing in cancer models. This study's approach enhances the interpretability of anti-cancer drug assays and informs more precise preclinical evaluation workflows.

• Bufuralol Hydrochloride: Advanced Protocols for β-Adrenergic

  2026-04-24

  Bufuralol hydrochloride empowers next-generation cardiovascular pharmacology and β-adrenergic modulation studies through validated workflows in hiPSC-derived organoid and animal models. This article unpacks protocol enhancements, troubleshooting strategies, and evidence-based innovations that set this versatile compound apart for translational and in vitro research.

• SARS-CoV-2 N Protein Disrupts GADD34-Mediated Antiviral Immu

  2026-04-23

  This study reveals a novel mechanism by which the SARS-CoV-2 nucleocapsid protein impairs host antiviral defenses: by sequestering GADD34 mRNA into atypical stress foci, the virus suppresses interferon signaling. These findings deepen our understanding of viral immune evasion and suggest new avenues for dissecting stress granule and innate immune pathways.

• Gastric Cancer Assembloid Models: Integrating Organoids and

  2026-04-23

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids with diverse stromal cell subpopulations, capturing the complexity of the tumor microenvironment. The model enables nuanced drug screening and mechanistic studies, revealing the critical influence of stromal cells on drug response and resistance.

• Vaccinia Virus F1L Inhibits NLRP1 Inflammasome via Ribotoxic

  2026-04-22

  This study elucidates how the vaccinia virus F1L protein inhibits NLRP1 inflammasome activation by blocking ZAKα-mediated ribotoxic stress responses in epithelial cells. The findings reveal a viral strategy for immune evasion and provide mechanistic clarity for researchers investigating inflammasome regulation and host-pathogen interactions.

15754 records 1/1051 page Next 12345 下5页 Last page